The announcement comes just weeks after President Trump publicly spread debunked claims that Tylenol consumption is linked to autism.

Considering Kenvue stock closed at $14.37 last week, that's a sizable premium K-C is paying -- about 46% -- and good reason ...

Kimberly-Clark Corp. will acquire Tylenol maker Kenvue Inc. in a cash and stock deal valued at almost $49 billion the two companies announced Nov. 3.

Kimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive ...

Crane Harbor Acquisition Corp (NASDAQ:CHAC) rose Monday after the company announced a merger deal with Xanadu Quantum Technologies to form a dedicated photonic quantum computing firm.

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.

Kimberly-Clark agreed to buy Kenvue in a cash-and-stock transaction that values the Tylenol maker at an enterprise value of ...